No Data
No Data
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
NewAmsterdam Pharma Company N.V.'s (NASDAQ:NAMS) Intrinsic Value Is Potentially 72% Above Its Share Price
Analysts Conflicted on These Healthcare Names: Allakos (ALLK), Edwards Lifesciences (EW) and NewAmsterdam Pharma Company (NAMS)
Newamsterdam Pharma Co Insider Sold Shares Worth $707,400, According to a Recent SEC Filing
NewAmsterdam Pharma Price Target Maintained With a $37.00/Share by Piper Sandler
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
Piper Sandler analyst Yasmeen Rahimi maintains $NewAmsterdam Pharma(NAMS.US)$ with a buy rating, and maintains the target price at $37.According to TipRanks data, the analyst has a success rate of 39.